NAMD submitted comments to the Centers for Medicare and Medicaid Services on the proposed rule on the Application of Mental Health Parity Requirements to Coverage Offered by Medicaid Managed Care Organizations, the Children’s Health Insurance Program (CHIP), and Alternative Benefit Plans. Read the full letter here.
In May 2015, NAMD held a workshop which brought together seven state teams to explore the challenges associated with increasing the delivery of person-centered long-term services and supports (LTSS) in the Medicaid program, with a particular focus on enhancing the delivery of home and community-based services (HCBS). This workshop was made possible by the financial […]
This memo provides an update on the House Energy and Commerce Committee’s 21st Century Cures initiative, which has undergone substantial revision since the release of its first legislative draft in January 2015. Read the full memo here.
NAMD recently released a memo addressing recommendations from the HHS Office of Inspector General (OIG) in response to audits and reviews of Medicaid Personal Care Services programs (PCS). Read the full memo here.
NAMD sent a letter to the Health Resources and Services Administration (HRSA) and the Centers for Medicare and Medicaid Services (CMS) to share our recent white paper discussing operational challenges in Medicaid’s interaction with the 340B drug discount program. The white paper is available here. Read the full letter here.
This NAMD working paper describes the challenges confronted by Medicaid programs in their interactions with the 340B drug discount program, including inconsistent guidance from federal agencies, the growth of contract pharmacy arrangements, and issues with Medicaid managed care programs. The paper also offers several recommendations to address the identified challenges. Read the full paper here.
The National Association of Medicaid Directors sent a letter to the leaders of the House Energy and Commerce Committee regarding the impact to the Medicaid program from federal legislative efforts to incentivize and expedite high-cost cure-like pharmaceutical treatments and devices. Read the full letter here.